Last reviewed · How we verify
Drospirenone Ethinyl estradiol Myo-inositol
This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters.
This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters. Used for Contraception, Polycystic ovary syndrome (PCOS) management, Irregular menstrual cycles with metabolic dysfunction.
At a glance
| Generic name | Drospirenone Ethinyl estradiol Myo-inositol |
|---|---|
| Sponsor | AGUNCO Obstetrics and Gynecology Centre |
| Drug class | Oral contraceptive with insulin sensitizer |
| Target | Progesterone receptor, estrogen receptor, inositol signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Drospirenone (a progestin) and ethinyl estradiol (an estrogen) work synergistically to inhibit the luteinizing hormone (LH) surge and suppress follicle-stimulating hormone (FSH), preventing ovulation. Myo-inositol, an insulin sensitizer, is added to potentially improve ovulatory function, reduce androgen levels, and enhance metabolic outcomes in women with polycystic ovary syndrome (PCOS) or metabolic dysfunction.
Approved indications
- Contraception
- Polycystic ovary syndrome (PCOS) management
- Irregular menstrual cycles with metabolic dysfunction
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS (NA)
- Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: